^ abSellers EM (April 2018). "Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 2: Optimizing the Design of Human Abuse Potential Studies". J Clin Psychopharmacol. 38 (2): 113–118. doi:10.1097/JCP.0000000000000838. PMID29360651. S2CID3506269.
^ abFoltin RW, Fischman MW (June 1991). "Assessment of abuse liability of stimulant drugs in humans: a methodological survey". Drug Alcohol Depend. 28 (1): 3–48. doi:10.1016/0376-8716(91)90052-z. PMID1679387.
^Volkow ND, Swanson JM (November 2003). "Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD". Am J Psychiatry. 160 (11): 1909–18. doi:10.1176/appi.ajp.160.11.1909. PMID14594733.
^Griffiths RR, Roache JD (1985). "Abuse Liability of Benzodiazepines:A Review of Human Studies Evaluating Subjective and/or Reinforcing Effects". The Benzodiazepines: Current Standards for Medical Practice. Springer Netherlands. pp. 209–225. doi:10.1007/978-94-009-4886-0_16. ISBN978-94-010-8663-9.
^Kalman D, Smith SS (June 2005). "Does nicotine do what we think it does? A meta-analytic review of the subjective effects of nicotine in nasal spray and intravenous studies with smokers and nonsmokers". Nicotine Tob Res. 7 (3): 317–33. doi:10.1080/14622200500125385. PMID16085500.
^Griffiths RR, Woodson PP (February 1988). "Reinforcing properties of caffeine: studies in humans and laboratory animals". Pharmacol Biochem Behav. 29 (2): 419–27. doi:10.1016/0091-3057(88)90180-3. PMID3283780. S2CID25399469.